Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1990 Aug;45(8):606–610. doi: 10.1136/thx.45.8.606

Evidence for protein oedema, neutrophil influx, and enhanced collagen production in lungs of patients with systemic sclerosis.

N K Harrison 1, R J McAnulty 1, P L Haslam 1, C M Black 1, G J Laurent 1
PMCID: PMC462642  PMID: 2402723

Abstract

Bronchoalveolar lavage fluid from patients with systemic sclerosis was analysed for evidence of pulmonary vascular leakage, inflammatory cell influx, and enhanced type III collagen synthesis. Eighteen patients with systemic sclerosis and computed tomographic evidence of fibrosing alveolitis were compared with 16 patients with a normal scan. The albumin concentration in lavage fluid was higher in all patients than in normal volunteers. Patients with an abnormal computed tomogram as a group had increased proportions of all inflammatory cell types, whereas those with a normal scan had increased neutrophils only. Increased lavage type III procollagen peptides were found in all patients with an abnormal computed tomogram and eight of those with a normal scan. These results suggest that pulmonary vascular leakage and neutrophil influx may be early pathological features of lung disease in systemic sclerosis and frequently associated with enhanced collagen production. Thus lavage of patients with systemic sclerosis may identify lung inflammation and altered collagen metabolism early in the evolution of fibrosing alveolitis.

Full text

PDF
606

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bateman E. D., Turner-Warwick M., Haslam P. L., Adelmann-Grill B. C. Cryptogenic fibrosing alveolitis: prediction of fibrogenic activity from immunohistochemical studies of collagen types in lung biopsy specimens. Thorax. 1983 Feb;38(2):93–101. doi: 10.1136/thx.38.2.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bentsen K. D., Hørslev-Petersen K., Junker P., Juhl E., Lorenzen I. Serum aminoterminal procollagen type III peptide in acute viral hepatitis. A long-term follow-up study. Liver. 1987 Apr;7(2):96–105. doi: 10.1111/j.1600-0676.1987.tb00324.x. [DOI] [PubMed] [Google Scholar]
  3. Bitterman P. B., Rennard S. I., Hunninghake G. W., Crystal R. G. Human alveolar macrophage growth factor for fibroblasts. Regulation and partial characterization. J Clin Invest. 1982 Oct;70(4):806–822. doi: 10.1172/JCI110677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bjermer L., Engström-Laurent A., Lundgren R., Rosenhall L., Hällgren R. Hyaluronate and type III procollagen peptide concentrations in bronchoalveolar lavage fluid as markers of disease activity in farmer's lung. Br Med J (Clin Res Ed) 1987 Oct 3;295(6602):803–806. doi: 10.1136/bmj.295.6602.803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bjermer L., Lundgren R., Hällgren R. Hyaluronan and type III procollagen peptide concentrations in bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis. Thorax. 1989 Feb;44(2):126–131. doi: 10.1136/thx.44.2.126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bjermer L., Thunell M., Hällgren R. Procollagen III peptide in bronchoalveolar lavage fluid. A potential marker of altered collagen synthesis reflecting pulmonary disease in sarcoidosis. Lab Invest. 1986 Dec;55(6):654–656. [PubMed] [Google Scholar]
  7. Breul S. D., Bradley K. H., Hance A. J., Schafer M. P., Berg R. A., Crystal R. G. Control of collagen production by human diploid lung fibroblasts. J Biol Chem. 1980 Jun 10;255(11):5250–5260. [PubMed] [Google Scholar]
  8. D'Angelo W. A., Fries J. F., Masi A. T., Shulman L. E. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969 Mar;46(3):428–440. doi: 10.1016/0002-9343(69)90044-8. [DOI] [PubMed] [Google Scholar]
  9. Fine A., Goldstein R. H. The effect of transforming growth factor-beta on cell proliferation and collagen formation by lung fibroblasts. J Biol Chem. 1987 Mar 15;262(8):3897–3902. [PubMed] [Google Scholar]
  10. Harrison N. K., Glanville A. R., Strickland B., Haslam P. L., Corrin B., Addis B. J., Lawrence R., Millar A. B., Black C. M., Turner-Warwick M. Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance. Respir Med. 1989 Sep;83(5):403–414. doi: 10.1016/s0954-6111(89)80072-1. [DOI] [PubMed] [Google Scholar]
  11. Haslam P. L., Turton C. W., Lukoszek A., Salsbury A. J., Dewar A., Collins J. V., Turner-Warwick M. Bronchoalveolar lavage fluid cell counts in cryptogenic fibrosing alveolitis and their relation to therapy. Thorax. 1980 May;35(5):328–339. doi: 10.1136/thx.35.5.328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hay J. G., Haslam P. L., Dewar A., Addis B., Turner-Warwick M., Laurent G. J. Development of acute lung injury after the combination of intravenous bleomycin and exposure to hyperoxia in rats. Thorax. 1987 May;42(5):374–382. doi: 10.1136/thx.42.5.374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hesterberg T. W., Gerriets J. E., Reiser K. M., Jackson A. C., Cross C. E., Last J. A. Bleomycin-induced pulmonary fibrosis: correlation of biochemical, physiological, and histological changes. Toxicol Appl Pharmacol. 1981 Sep 15;60(2):360–367. doi: 10.1016/0041-008x(91)90239-b. [DOI] [PubMed] [Google Scholar]
  14. Kirk J. M., Da Costa P. E., Turner-Warwick M., Littleton R. J., Laurent G. J. Biochemical evidence for an increased and progressive deposition of collagen in lungs of patients with pulmonary fibrosis. Clin Sci (Lond) 1986 Jan;70(1):39–45. doi: 10.1042/cs0700039. [DOI] [PubMed] [Google Scholar]
  15. König G., Luderschmidt C., Hammer C., Adelmann-Grill B. C., Braun-Falco O., Fruhmann G. Lung involvement in scleroderma. Chest. 1984 Mar;85(3):318–324. doi: 10.1378/chest.85.3.318. [DOI] [PubMed] [Google Scholar]
  16. Low R. B., Cutroneo K. R., Davis G. S., Giancola M. S. Lavage type III procollagen N-terminal peptides in human pulmonary fibrosis and sarcoidosis. Lab Invest. 1983 Jun;48(6):755–759. [PubMed] [Google Scholar]
  17. Majewski S., Skiendzielewska A., Makieła B., Jablońska S., Błaszczyk M. Serum levels of type III collagen aminopropeptide in patients with systemic scleroderma. Arch Dermatol Res. 1987;279(7):484–486. doi: 10.1007/BF00412596. [DOI] [PubMed] [Google Scholar]
  18. Martinet Y., Rom W. N., Grotendorst G. R., Martin G. R., Crystal R. G. Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis. N Engl J Med. 1987 Jul 23;317(4):202–209. doi: 10.1056/NEJM198707233170404. [DOI] [PubMed] [Google Scholar]
  19. Postlethwaite A. E., Kang A. H. Characterization of fibroblast proliferation factors elaborated by antigen- and mitogen-stimulated guinea pig lymph node cells: differentiation from lymphocyte-derived chemotactic factor for fibroblasts, lymphocyte mitogenic factor, and interleukin 1. Cell Immunol. 1982 Oct;73(1):169–178. doi: 10.1016/0008-8749(82)90445-2. [DOI] [PubMed] [Google Scholar]
  20. Rohde H., Langer I., Krieg T., Timpl R. Serum and urine analysis of the aminoterminal procollagen peptide type III by radioimmunoassay with antibody Fab fragments. Coll Relat Res. 1983 Sep;3(5):371–379. doi: 10.1016/s0174-173x(83)80018-1. [DOI] [PubMed] [Google Scholar]
  21. Rohde H., Vargas L., Hahn E., Kalbfleisch H., Bruguera M., Timpl R. Radioimmunoassay for type III procollagen peptide and its application to human liver disease. Eur J Clin Invest. 1979 Dec;9(6):451–459. doi: 10.1111/j.1365-2362.1979.tb00912.x. [DOI] [PubMed] [Google Scholar]
  22. Rossi G. A., Bitterman P. B., Rennard S. I., Ferrans V. J., Crystal R. G. Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis. Am Rev Respir Dis. 1985 Apr;131(4):612–617. doi: 10.1164/arrd.1985.131.4.612. [DOI] [PubMed] [Google Scholar]
  23. Selman M., Montaño M., Ramos C., Chapela R. Concentration, biosynthesis and degradation of collagen in idiopathic pulmonary fibrosis. Thorax. 1986 May;41(5):355–359. doi: 10.1136/thx.41.5.355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Silver R. M., Metcalf J. F., Stanley J. H., LeRoy E. C. Interstitial lung disease in scleroderma. Analysis by bronchoalveolar lavage. Arthritis Rheum. 1984 Nov;27(11):1254–1262. doi: 10.1002/art.1780271107. [DOI] [PubMed] [Google Scholar]
  25. Strickland B., Brennan J., Denison D. M. Computed tomography in diffuse lung disease: improving the image. Clin Radiol. 1986 Jul;37(4):335–338. doi: 10.1016/s0009-9260(86)80265-3. [DOI] [PubMed] [Google Scholar]
  26. Strickland B. Imaging fibrosing alveolitis. Postgrad Med J. 1988;64 (Suppl 4):35–40. [PubMed] [Google Scholar]
  27. Thrall R. S., McCormick J. R., Jack R. M., McReynolds R. A., Ward P. A. Bleomycin-induced pulmonary fibrosis in the rat: inhibition by indomethacin. Am J Pathol. 1979 Apr;95(1):117–130. [PMC free article] [PubMed] [Google Scholar]
  28. Wallaert B., Hatron P. Y., Grosbois J. M., Tonnel A. B., Devulder B., Voisin C. Subclinical pulmonary involvement in collagen-vascular diseases assessed by bronchoalveolar lavage. Relationship between alveolitis and subsequent changes in lung function. Am Rev Respir Dis. 1986 Apr;133(4):574–580. doi: 10.1164/arrd.1986.133.4.574. [DOI] [PubMed] [Google Scholar]
  29. Wangensteen D., Yankovich R., Hoidal J., Niewoehner D. Bleomycin-induced changes in pulmonary microvascular albumin permeability and extravascular albumin space. Am Rev Respir Dis. 1983 Feb;127(2):204–208. doi: 10.1164/arrd.1983.127.2.204. [DOI] [PubMed] [Google Scholar]
  30. Weaver A. L., Divertie M. B., Titus J. L. Pulmonary scleroderma. Dis Chest. 1968 Dec;54(6):490–498. doi: 10.1378/chest.54.6.490. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES